Abstract
The concept of fluorodeoxyglucose positron emission tomography (FDG PET) was conceived in the early 1970s by a number of researchers. In August 1976, the first brain and whole-body images were acquired successfully using the initial type of PET scanner optimized for in vivo imaging with positron-emitting radionuclides in humans (Phelps et al. J Nucl Med 16(3):210–24, 1975). This demonstrated the feasibility of the methodology, but it was still far from clinical study.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16(3):210–24.
Tashiro M, Kubota K, Ito M, Fujimoto T, Yamaguchi K, Sasaki H, Moser E. Clinical PET activities in European and Asia-Oceanian countries. Kaku Igaku. 2001;38(3):255–67.
Mansuet M, Grimaldi A, Mangili G, Picchio M, Giovacchini G, Vigano R, Messa C, Fazio F. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis. Eur J Cancer Care. 2009;18:612–9.
van Hooren ACG, Brouwer J, de Bree R, Hoekstra OS, Leemans CR, Uyl-de Groot CA. The cost-effectiveness of 18FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur Arch Otorhinolaryngol. 2009;266:1441–8.
Sher DJ, Tishler RB, Annino D, Punglia RS. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Ann Oncol. 15 Oct 2009; 21(5):1072–7
Yen RF, Yen MF, Hong RL, Tzen KY, Chien CR, Chen TH. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma. Acad Radiol. 2009;16(1):54–60.
Mansueto M, Grimaldi A, Torbica A, Pepe G, Giovacchini G, Messa C, Fazio F. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison. Q J Nucl Med Mol Imag. 2007;51(3):224–34. Epub 1 Jun 2007.
Dietlein M, Schicha H. Reimbursement of the PET in oncology in Europe; a questionnaire based survey. Nuklearmedizin. 2003;42:80–5.
Krug B, Van Zanten A, Pirson AS, Crott R, Vander Borght T. Activity-based costing evaluation of [18F]-fludeoxyglucose production. Eur J Nucl Med Mol Imaging. 2008;35(1):80–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kim, SK., Kang, K.W., Lee, MC. (2013). Current Status of PET in the World. In: Kim, E., Lee, MC., Inoue, T., Wong, WH. (eds) Clinical PET and PET/CT. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0802-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0802-5_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0801-8
Online ISBN: 978-1-4419-0802-5
eBook Packages: MedicineMedicine (R0)